Publications by authors named "Andreas Muehler"

Claim this Profile
R
Randomized adaptive assessment of post COVID syndrome treatments (RAPID): a study protocol for a multicenter, randomized, controlled adaptive platform trial of treatment options for Post Covid Syndrome (PCS) on patients physical function including the first intervention specific appendix RAPID_REVIVE (reducing inflammatory activity in patients with PCS).
Lisa Weipert, Ralph G Telgmann, Gabriele Anton, Thomas Asendorf, Irina Chaplinskaja-Sobol, Andreas Muehler

Trials· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vidofludimus Calcium in Patients With Moderate-to-Severe Ulcerative Colitis: A Randomized, Placebo-Controlled, Phase 2 Trial.
Geert D'Haens, Kalina Grivcheva Stardelova, Edite Sadiku, Natallia Kizlova, Syitlana Skybalo, Andreas Muehler

Clin Transl Gastroenterol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, clinical activity, pharmacodynamics, and pharmacokinetics of IMU-856, a SIRT6 modulator, in coeliac disease: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial.
A James M Daveson, Richard Stubbs, Thomas M Polasek, Jorma Isola, Robert Anderson, Andreas Muehler

Lancet Gastroenterol Hepatol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Dose-Response of Vidofludimus Calcium in Relapsing Multiple Sclerosis: Extended Results of a Placebo-Controlled Phase 2 Trial.
Robert J Fox, Heinz Wiendl, Christian Wolf, Nicola De Stefano, Johann Sellner, Andreas R Muehler

Neurol Neuroimmunol Neuroinflamm· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Tolerability, and Pharmacokinetics of IMU-935, a Novel Inverse Agonist of Retinoic Acid Receptor-Related Orphan Nuclear Receptor γt: Results From a Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study.
Thomas M Polasek, Indika Leelasena, Irina Betscheider, Marija Marolt, Hella Kohlhof, Andreas R Muehler

Clin Pharmacol Drug Dev· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Vidofludimus Calcium in Patients Hospitalized with COVID-19: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial.
Maria J G T Vehreschild, Petar Atanasov, Kateryna Yurko, Cristian Oancea, Georgi Popov, Andreas R Muehler

Infect Dis Ther· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanistic Impact of Different Ligand Scaffolds on FXR Modulation Suggests Avenues to Selective Modulators.
Jan Heering, Nathalie Jores, Whitney Kilu, Espen Schallmayer, Evelyn Peelen, Andreas Muehler

ACS Chem Biol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A double-blind, randomized, placebo-controlled phase 2 trial evaluating the selective dihydroorotate dehydrogenase inhibitor vidofludimus calcium in relapsing-remitting multiple sclerosis.
Robert J Fox, Heinz Wiendl, Christian Wolf, Nicola De Stefano, Johann Sellner, Andreas R Muehler

Ann Clin Transl Neurol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro.
Friedrich Hahn, Christina Wangen, Sigrun Häge, Antonia Sophia Peter, Gerhard Dobler, Andreas Muehler

Viruses· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical relevance of intestinal barrier dysfunction in common gastrointestinal diseases.
Andreas Muehler, Jason R Slizgi, Hella Kohlhof, Manfred Groeppel, Evelyn Peelen

World J Gastrointest Pathophysiol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Tolerability and Pharmacokinetics of Vidofludimus calcium (IMU-838) After Single and Multiple Ascending Oral Doses in Healthy Male Subjects.
Andreas Muehler, Hella Kohlhof, Manfred Groeppel, Daniel Vitt

Eur J Drug Metab Pharmacokinet· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vidofludimus calcium, a next generation DHODH inhibitor for the Treatment of relapsing-remitting multiple sclerosis.
Andreas Muehler, Evelyn Peelen, Hella Kohlhof, Manfred Gröppel, Daniel Vitt

Mult Scler Relat Disord· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Selective Oral Immunomodulator Vidofludimus in Patients with Active Rheumatoid Arthritis: Safety Results from the COMPONENT Study.
Andreas Muehler, Hella Kohlhof, Manfred Groeppel, Daniel Vitt

Drugs R D· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib in Adult Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Dysfunction.
Xiaofei Zhou, A Craig Lockhart, Siqing Fu, John Nemunaitis, John Sarantopoulos, Andreas Muehler

J Clin Pharmacol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of rifampin, itraconazole and esomeprazole on the pharmacokinetics of alisertib, an investigational aurora a kinase inhibitor in patients with advanced malignancies.
Xiaofei Zhou, Shubham Pant, John Nemunaitis, A Craig Lockhart, Gerald Falchook, Andreas Muehler

Invest New Drugs· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis